Avadel Operating Cycle from 2010 to 2026

AVDL Stock  USD 21.57  0.01  0.05%   
Avadel Pharmaceuticals Operating Cycle yearly trend continues to be quite stable with very little volatility. The value of Operating Cycle is projected to decrease to 351.48. From the period between 2010 and 2026, Avadel Pharmaceuticals, Operating Cycle regression line of its data series had standard deviation of  1,692 and standard deviation of  1,692. View All Fundamentals
 
Operating Cycle  
First Reported
2010-12-31
Previous Quarter
502.7
Current Value
351.48
Quarterly Volatility
1.7 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Avadel Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Avadel Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.6 M, Interest Expense of 13.1 M or Selling General Administrative of 218.6 M, as well as many indicators such as Price To Sales Ratio of 7.91, Dividend Yield of 0.0 or PTB Ratio of 12.8. Avadel financial statements analysis is a perfect complement when working with Avadel Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Avadel Stock
Check out the analysis of Avadel Pharmaceuticals Correlation against competitors.
Historical Operating Cycle data for Avadel Pharmaceuticals serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Avadel Pharmaceuticals PLC represents a compelling investment opportunity.

Latest Avadel Pharmaceuticals' Operating Cycle Growth Pattern

Below is the plot of the Operating Cycle of Avadel Pharmaceuticals PLC over the last few years. It is Avadel Pharmaceuticals' Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Avadel Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Operating Cycle10 Years Trend
Slightly volatile
   Operating Cycle   
       Timeline  

Avadel Operating Cycle Regression Statistics

Arithmetic Mean1,122
Geometric Mean489.59
Coefficient Of Variation150.71
Mean Deviation1,240
Median351.48
Standard Deviation1,692
Sample Variance2.9M
Range4.5K
R-Value0.39
Mean Square Error2.6M
R-Squared0.15
Significance0.12
Slope131.55
Total Sum of Squares45.8M

Avadel Operating Cycle History

2026 351.48
2025 502.7
2024 558.55
2021 4636.35
2020 633.81
2019 181.28
2018 148.57

About Avadel Pharmaceuticals Financial Statements

Avadel Pharmaceuticals investors utilize fundamental indicators, such as Operating Cycle, to predict how Avadel Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Operating Cycle 502.70  351.48 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Avadel Pharmaceuticals is a strong investment it is important to analyze Avadel Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Avadel Pharmaceuticals' future performance. For an informed investment choice regarding Avadel Stock, refer to the following important reports:
Check out the analysis of Avadel Pharmaceuticals Correlation against competitors.
You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avadel Pharmaceuticals. If investors know Avadel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Avadel Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Revenue Per Share
2.57
Quarterly Revenue Growth
0.549
Return On Assets
(0)
Return On Equity
(0)
Understanding Avadel Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Avadel's accounting equity. The concept of intrinsic value - what Avadel Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Avadel Pharmaceuticals' price substantially above or below its fundamental value.
Understanding that Avadel Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Avadel Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Avadel Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.